Related Experiment Video
Updated: Jun 23, 2026
11:44
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Targeting the eicosanoid pathway in non-small-cell lung cancer
Leora Horn1, Michael Backlund, David H Johnson
1Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, Division of Hematology & Medical Oncology, 2220 Pierce Avenue, Nashville, TN 37232, USA.
Expert Opinion on Therapeutic Targets
|May 5, 2009
Summary
Cyclooxygenase-2 (COX-2) upregulation is an early event in non-small-cell lung cancer development. Inhibitors of COX-2 are being studied for lung cancer prevention and treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Cyclooxygenase-2 (COX-2) upregulation is implicated as an early event in non-small-cell lung cancer (NSCLC) development.
- Tumors with elevated COX-2 synthesize prostaglandin E₂ (PGE₂), linked to increased proangiogenic factors and metastatic potential.
Purpose of the Study:
- To investigate the role of COX-2 in lung cancer development and progression.
- To explore the potential of COX-2 inhibitors for chemoprevention and therapy in lung cancer.
Main Methods:
- Review of preclinical data and existing evidence on COX-2 expression in NSCLC.
- Analysis of the association between COX-2, PGE₂, and tumor characteristics.
Main Results:
- Evidence suggests COX-2 upregulation is an early event in NSCLC.
- Elevated COX-2 correlates with increased PGE₂ synthesis, proangiogenesis, and metastatic potential.
- COX-2 may significantly contribute to lung cancer growth and invasiveness.
Conclusions:
- COX-2 plays a critical role in lung cancer development, growth, and metastasis.
- COX-2 inhibitors are under investigation for their potential in lung cancer chemoprevention and treatment.
